FDA clears IND application for ‘controllable’ CAR-T to treat advanced multiple myeloma

Sumary of FDA clears IND application for ‘controllable’ CAR-T to treat advanced multiple myeloma:

• The FDA cleared an investigational new drug application for ACLX-001, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma, according to the agent manufacturer..
• ACLX-001 (Arcellx) is an autologous, gene-edited CAR T-cell therapy with a novel binding domain that targets the B-cell maturation antigen (BCMA) on the surface of cancer cells..
• The investigational therapy binding domain was developed using Arcellx proprietary platform, in which antigen receptor complex T cells (ARC-T) are controlled by a tumor-targeting protein called a SparX (soluble protein antigen-receptor X-linker)..
• “ARC-T cells cannot recognize the tumor without SparX proteins and can only destroy a diseased cell when attached to a SparX-antigen complex,”.
• Data presented at last year virtual ASH Annual Meeting showed all six patients responded to therapy, with four achieving complete stringent response..
• “Demonstrating a safe and effective cell therapy that is controllable and adaptable has the potential to be transformative for the field of cell and gene therapy,”…

Want to know more click here go to source.

From Healio - April 8, 2021